A Study of SCG101 TCR-T Cell Therpay in the Treatment of Subjects With Hepatitis B Virus-Related

This study is testing SCG101, a type of engineered T-cell therapy (called TCR-T cell therapy) that targets the hepatitis B virus, in patients with liver cancer (hepatocellular carcinoma) that is related to hepatitis B virus infection. The immune cells are modified to recognize and attack cancer cells that carry the virus. **You may be eligible if...** - You have been confirmed to have hepatitis B virus-related hepatocellular carcinoma (HCC) - You have already received standard systemic treatments for liver cancer - You carry a specific immune marker (HLA-A*02) - Your cancer is classified as Barcelona Clinic Liver Cancer stage B or C - Your liver is functioning reasonably well (Child-Pugh score ≤ 7) - You test positive for the hepatitis B surface antigen (HBsAg) but negative for HBeAg - You have at least one measurable tumor and a life expectancy of at least 3 months **You may NOT be eligible if...** - You have another primary cancer diagnosed within the last 5 years - You have brain metastases or active liver failure (hepatic encephalopathy) - You have severe fluid buildup in the abdomen Talk to your doctor to see if this trial is right for you.